The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 45(2017), 3, Seite 455-467 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elbasha, E. H [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1111/apt.13882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1991092121 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1991092121 | ||
| 003 | DE-627 | ||
| 005 | 20230514092723.0 | ||
| 007 | tu | ||
| 008 | 170303s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.13882 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1991092121 | ||
| 035 | |a (DE-599)GBVOLC1991092121 | ||
| 035 | |a (PRQ)c1342-5417fb6245abbbed4f7772136bf4470d528ca4aa3274032cf7077405e96f88410 | ||
| 035 | |a (KEY)0157873120170000045000300455costeffectivenessoftestingforns5aresistanceassocia | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a 44.87 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Elbasha, E. H |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 540 | |a Nutzungsrecht: © 2016 Merck Sharp & Dohme Corp. published by John Wiley & Sons Ltd. | ||
| 700 | 1 | |a Robertson, M. N |4 oth | |
| 700 | 1 | |a Nwankwo, C |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d Oxford : Wiley-Blackwell, 1987 |g 45(2017), 3, Seite 455-467 |w (DE-627)130433233 |w (DE-600)639012-2 |w (DE-576)028460936 |x 0269-2813 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2017 |g number:3 |g pages:455-467 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1111/apt.13882 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1111/apt.13882/abstract |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.87 |q AVZ |
| 936 | b | k | |a 44.38 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 45 |j 2017 |e 3 |h 455-467 | ||